Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A1 | P68400 | 4/20 | 0.35 |
| ▸ | TTK | P33981 | 6/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | MAPK8 | P45983 | 4/20 | 0.33 |
| ▸ | MAPK9 | P45984 | 4/20 | 0.33 |
| ▸ | MAPK10 | P53779 | 4/20 | 0.33 |
| ▸ | CSNK2B | P67870 | 2/20 | 0.32 |
| ▸ | CDK2 | P24941 | 4/20 | 0.32 |
| ▸ | CDK9 | P50750 | 4/20 | 0.32 |
| ▸ | CDK4 | P11802 | 1/20 | 0.31 |
| ▸ | CDK7 | P50613 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12645369 | 0.89 | CSNK2A1 (0.41) | CSNK2A1TTKCYP3A4MAPK8MAPK9 | |
| SCHEMBL12644899 | 0.88 | TTK (0.36) | CSNK2A1TTKCYP3A4MAPK8MAPK9 | |
| SCHEMBL12644721 | 0.87 | CSNK2B (0.38) | CSNK2A1TTKMAPK8MAPK9MAPK10 | |
| SCHEMBL12645620 | 0.86 | JAK2 (0.35) | CSNK2A1TTKCYP3A4MAPK8MAPK9 | |
| SCHEMBL12645072 | 0.86 | CDK2 (0.39) | CSNK2A1TTKCYP3A4MAPK8MAPK9 | |
| SCHEMBL12644914 | 0.85 | CSNK2A1 (0.35) | CSNK2A1TTKCYP3A4MAPK8MAPK9 | |
| SCHEMBL2030474 | 0.85 | MAPK8 (0.37) | CSNK2A1TTKMAPK8MAPK9MAPK10 | |
| SCHEMBL2030477 | 0.85 | MAPK8 (0.37) | CSNK2A1TTKMAPK8MAPK9MAPK10 | |
| SCHEMBL2030472 | 0.85 | MAPK8 (0.37) | CSNK2A1TTKMAPK8MAPK9MAPK10 | |
| SCHEMBL12644942 | 0.85 | MAPK8 (0.39) | CSNK2A1TTKMAPK8MAPK9MAPK10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9303033-B2 | Pyrazolopyrimidines and related heterocycles as CK2 inhibitors | SENHWA BIOSCIENCES, INC. (TW) | 2016-04-05 | — | — | US | disclosed |
| US-8575177-B2 | Pyrazolopyrimidines and related heterocycles as CK2 inhibitors | SENHWA BIOSCIENCES, INC. (TW) | 2013-11-05 | — | — | US | disclosed |
| US-20110152240-A1 | PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS CK2 INHIBITORS | CYLENE PHARMACEUTICALS, INC. (US) | 2011-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110152240-A1 | PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS CK2 INHIBITORS | CDK2, CKS2, CSNK2A1 | CSNK2A1 3/4885TTK 87/4885CYP3A4 1892/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.